在使用Campath-1H进行长期治疗的难治性B细胞慢性淋巴细胞白血病中，加用阿德福韦治疗乙肝复发感染。

Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.

作者信息

Cortelezzi Agostino, Viganò Mauro, Zilioli Vittorio R, Fantini Norma N, Pasquini Maria C, Deliliers Giorgio Lambertenghi, Colombo Massimo, Lampertico Pietro

机构信息

Hematology 1-Bone Marrow Transplantation Unit and the IRCCS Fondazione Ospedale Maggiore, University of Milan, via Francesco Sforza 35, 20122 Milan, Italy.

出版信息

J Clin Virol. 2006 Apr;35(4):467-9. doi: 10.1016/j.jcv.2005.10.009. Epub 2005 Nov 28.

DOI:10.1016/j.jcv.2005.10.009

PMID:16316778

Abstract

We describe a case of severe reactivation of occult hepatitis B virus infection in a 49-year-old man, who was treated with high doses of chlorambucil for a Binet stage A B-cell chronic lymphocytic leukemia (B-CLL). The patient was initially treated with lamivudine and subsequently with lamivudine and adefovir dipivoxil combination therapy to control viral replication and allow for long-term anti-cancer chemotherapy with alemtuzumab (Campath-1H), which was introduced to rescue for a B-CLL relapse. During 20 months of anti-HBV therapy, ALT and HBV-DNA levels progressively declined and B-CLL was successfully kept under control by long-term alemtuzumab administration.

摘要

我们描述了一例49岁男性隐匿性乙型肝炎病毒感染严重复发的病例，该患者因Binet A期B细胞慢性淋巴细胞白血病（B-CLL）接受了高剂量苯丁酸氮芥治疗。患者最初接受拉米夫定治疗，随后接受拉米夫定和阿德福韦酯联合治疗以控制病毒复制，并允许使用阿仑单抗（Campath-1H）进行长期抗癌化疗，引入阿仑单抗是为了挽救B-CLL复发。在20个月的抗HBV治疗期间，ALT和HBV-DNA水平逐渐下降，通过长期给予阿仑单抗成功控制了B-CLL。